| Dr Andrew Dickens, MD | |
|
2122 Manchester Expy, Columbus, GA 31904-6878 | |
| (706) 596-4000 | |
| Not Available |
| Full Name | Dr Andrew Dickens |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 33 Years |
| Location | 2122 Manchester Expy, Columbus, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366405292 | NPI | - | NPPES |
| 000708122B | Medicaid | GA | |
| 596476 | Other | GA | STATE BENEFIT PLAN |
| 596476 | Other | GA | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 038218 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Hospital- Emory Healthcare | Columbus, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Associates Of Columbus Pa | 6901701135 | 26 |
News Archive
BAC, the leading provider of antibody-based affinity purification technologies, announces the launch of CaptureSelect HumanPlasma14 for highly specific, reproducible depletion of the 14 most abundant proteins from human blood plasma or serum. HumanPlasma14 is designed for single-step, single-use depletion of more than 99% of the abundant proteins.
A six-month outpatient prevention programme conducted by nurses has resulted in significant and sustained improvements in the control of cardiovascular risk factors, including high cholesterol or high blood pressure, in patients hospitalised for a heart attack or impending heart attack.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted its complete response to the Complete Response (CR) letter issued by the U.S. Food & Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles.
Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations - larger-scale rearrangements of DNA that can encompass large chunks of chromosomes - disturb carefully balanced mechanisms that have evolved to regulate cell growth.
› Verified 1 days ago
| Entity Name | Anesthesia Associates Of Columbus Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740251248 PECOS PAC ID: 6901701135 Enrollment ID: O20031202000054 |
News Archive
BAC, the leading provider of antibody-based affinity purification technologies, announces the launch of CaptureSelect HumanPlasma14 for highly specific, reproducible depletion of the 14 most abundant proteins from human blood plasma or serum. HumanPlasma14 is designed for single-step, single-use depletion of more than 99% of the abundant proteins.
A six-month outpatient prevention programme conducted by nurses has resulted in significant and sustained improvements in the control of cardiovascular risk factors, including high cholesterol or high blood pressure, in patients hospitalised for a heart attack or impending heart attack.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted its complete response to the Complete Response (CR) letter issued by the U.S. Food & Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles.
Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations - larger-scale rearrangements of DNA that can encompass large chunks of chromosomes - disturb carefully balanced mechanisms that have evolved to regulate cell growth.
› Verified 1 days ago
| Entity Name | Emory Specialty Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407864168 PECOS PAC ID: 3476559782 Enrollment ID: O20061010000447 |
News Archive
BAC, the leading provider of antibody-based affinity purification technologies, announces the launch of CaptureSelect HumanPlasma14 for highly specific, reproducible depletion of the 14 most abundant proteins from human blood plasma or serum. HumanPlasma14 is designed for single-step, single-use depletion of more than 99% of the abundant proteins.
A six-month outpatient prevention programme conducted by nurses has resulted in significant and sustained improvements in the control of cardiovascular risk factors, including high cholesterol or high blood pressure, in patients hospitalised for a heart attack or impending heart attack.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted its complete response to the Complete Response (CR) letter issued by the U.S. Food & Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles.
Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations - larger-scale rearrangements of DNA that can encompass large chunks of chromosomes - disturb carefully balanced mechanisms that have evolved to regulate cell growth.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Dickens, MD Po Box 235019, Montgomery, AL 36123-5019 Ph: (334) 279-1450 | Dr Andrew Dickens, MD 2122 Manchester Expy, Columbus, GA 31904-6878 Ph: (706) 596-4000 |
News Archive
BAC, the leading provider of antibody-based affinity purification technologies, announces the launch of CaptureSelect HumanPlasma14 for highly specific, reproducible depletion of the 14 most abundant proteins from human blood plasma or serum. HumanPlasma14 is designed for single-step, single-use depletion of more than 99% of the abundant proteins.
A six-month outpatient prevention programme conducted by nurses has resulted in significant and sustained improvements in the control of cardiovascular risk factors, including high cholesterol or high blood pressure, in patients hospitalised for a heart attack or impending heart attack.
Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted its complete response to the Complete Response (CR) letter issued by the U.S. Food & Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles.
Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.
In cancer cells, genetic errors wreak havoc. Misspelled genes, as well as structural variations - larger-scale rearrangements of DNA that can encompass large chunks of chromosomes - disturb carefully balanced mechanisms that have evolved to regulate cell growth.
› Verified 1 days ago
Dr. Hares Akbary, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7351 Old Moon Rd, Columbus, GA 31909 Phone: 706-653-7000 Fax: 706-653-7800 | |
Christopher M Jones, MD10/05/1962 Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 616 19th St, Columbus, GA 31901 Phone: 706-494-4262 | |
Rajesh Arora, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 710 Center St, Columbus, GA 31901 Phone: 706-571-1427 Fax: 706-660-2686 | |
Dr. Harold Jarrell, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2122 Manchester Expy, Columbus, GA 31904 Phone: 706-596-4000 | |
Dr. Sidney Bedell, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2067 Osprey Cove Dr, Columbus, GA 31904 Phone: 770-883-7660 Fax: 478-352-0095 | |
Shaun R. Williams, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2122 Manchester Expressway, Columbus, GA 31904 Phone: 334-279-1450 Fax: 334-395-4110 | |
Dr. Sung Kyu Chang, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7351 Old Moon Rd, Columbus, GA 31909 Phone: 706-653-7000 Fax: 706-653-7800 |